# Safety Study to Evaluate the Occurrence of EFAD in Pediatric Patients With PNAC Who Require More Than Eight Weeks of Omegaven Treatment

> **NCT06274788** · — · RECRUITING · sponsor: **Fresenius Kabi** · enrollment: 40 (estimated)

## Conditions studied

- Parenteral Nutrition Associated Liver Disease (PNALD)
- Essential Fatty Acid Deficiency
- Malnutrition
- Pediatric ALL

## Interventions

- **DRUG:** Omegaven® (fish oil triglycerides) Injectable Emulsion

## Key facts

- **NCT ID:** NCT06274788
- **Lead sponsor:** Fresenius Kabi
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2024-12-15
- **Primary completion:** 2026-03-01
- **Final completion:** 2027-03-01
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2025-09-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06274788

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06274788, "Safety Study to Evaluate the Occurrence of EFAD in Pediatric Patients With PNAC Who Require More Than Eight Weeks of Omegaven Treatment". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT06274788. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*